New drug targets Hard-to-Treat cancers with missing gene

NCT ID NCT03284385

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 30 times

Summary

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that have a missing SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The goal is to see if it can shrink or control tumors in people who have already tried other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Northwestern University

Chicago, Illinois, 60611, United States
Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
UCSF Medical Center-Mount Zion

San Francisco, California, 94115, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
Vanderbilt Breast Center at One Hundred Oaks

Nashville, Tennessee, 37204, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA LOCALLY ADVANCED CLEAR CELL RENAL CELL CARCINOMA LOCALLY ADVANCED MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT SOLID NEOPLASM METASTATIC RENAL CELL CARCINOMA STAGE III RENAL CELL CANCER AJCC V8 STAGE IV RENAL CELL CANCER AJCC V8 STAGE IV RENAL CELL CANCER AJCC V8